Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
TCF-3 CRISPR/Cas9 KO Plasmid (h): sc-400821
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- TCF-3 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the TCF-3 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: TCF-3 Antibody (E-2): sc-166411
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
TCF-3 CRISPR/Cas9 KO Plasmid (h) | sc-400821 | 20 µg | $397.00 |
Overview
TCF7L1 encodes the transcription factor TCF-3, a high-mobility group (HMG) DNA-binding protein that functions as a context-dependent regulator of gene expression downstream of canonical Wnt/β-catenin signaling. By partnering with β-catenin or transcriptional corepressors, TCF-3 helps control cell fate decisions, proliferation, and lineage specification programs, including stem and progenitor cell maintenance. TCF7L1 activity intersects with developmental and differentiation pathways and contributes to chromatin-state regulation at Wnt-responsive enhancers. Dysregulated TCF7L1/TCF-3 signaling has been studied in relation to altered differentiation states and proliferative phenotypes in disease-relevant cellular models, including cancer-associated Wnt pathway perturbations.
TCF-3 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the TCF7L1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the TCF7L1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the TCF7L1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish TCF-3 protein expression.
This CRISPR knockout system enables efficient generation of TCF7L1-deficient cell models for investigation of TCF-3 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting TCF7L1 exon(s) critical for TCF-3 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple TCF7L1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by TCF-3 CRISPR/Cas9 KO Plasmid (h) and TCF-3 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the TCF7L1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by TCF-3 HDR Plasmid (h) and TCF-3 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by TCF7L1 homology arms to support homology-directed repair at defined TCF7L1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.